Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi, Hai Yan
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 645-661
Closed Access | Times Cited: 247

Showing 51-75 of 247 citing articles:

Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Younghoon Kim, Jaewon Song, Namkyoung Kim, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Treatment of Isocitrate Dehydrogenase-Mutant Gliomas
Sofia Chernet, Hannah Kim, Ankush Bhatia, et al.
Advances in Oncology (2025)
Closed Access
D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming
Fengchao Lang, Karambir Kaur, Haiqing Fu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Recent advances in chemodynamic nanotherapeutics to overcome multidrug resistance in cancers
Wenjia Xu, Min Wang, Xinyu Liu, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117901-117901
Closed Access
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
Muhammad Tufail, Canhua Jiang, Ning Li
Military Medical Research (2025) Vol. 12, Iss. 1
Open Access
Penile angiosarcoma: A case report
Le He, Qi Xiang, Nan Yang, et al.
Asian Journal of Surgery (2025)
Open Access
Integrated Analysis of Cuproptosis Regulators Reveals Prognostic Significance and Therapeutic Targets in IDH1 Mutant Glioma
Yuxuan Luan, Yong Meng, Chunming Sun, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Establishment and characterization of NCC-dCS2-C1: a novel patient-derived cell line of dedifferentiated chondrosarcoma
Shuhei Iwata, Takuya Ono, Rei Noguchi, et al.
Human Cell (2025) Vol. 38, Iss. 3
Closed Access
CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma
Yu Huang, Yulu Ye, Tingzhuang Yi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
First Report of NSCLC With IDH1 Mutation: A Case Report
Yuyue Zhang, Yanmei Liu, Ganghui Ye, et al.
Clinical Lung Cancer (2025)
Closed Access
Exploring the oncogenic impact of heteroplasmic de novo MT-ND5 truncating mutations
Yuanyuan Wu, Jiangbin Ye, Zhenglong Gu
Mitochondrial Communications (2025)
Open Access
Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies
Yifan Wang, Hailong Bai, Aixin Wang, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 4
Closed Access
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Svetlana N. Aleksakhina, Evgeny N. Imyanitov
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10931-10931
Open Access | Times Cited: 31
PERK‐Mediated Cholesterol Excretion from IDH Mutant Glioma Determines Anti‐Tumoral Polarization of Microglia
Tao Wang, Yunxia Zhou, Yunping Fan, et al.
Advanced Science (2023) Vol. 10, Iss. 20
Open Access | Times Cited: 11
The impact of RNA binding proteins and the associated long non-coding RNAs in the TCA cycle on cancer pathogenesis
Tao Shen, Haiyang Wang, Bin Tang, et al.
RNA Biology (2023) Vol. 20, Iss. 1, pp. 223-234
Open Access | Times Cited: 11
Accuracy of Radiomics in Predicting IDH Mutation Status in Diffuse Gliomas: A Bivariate Meta-Analysis
Gianfranco Di Salle, Lorenzo Tumminello, Maria Elena Laino, et al.
Radiology Artificial Intelligence (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 11
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
Rishab Ramapriyan, Vivasvan S. Vykunta, Gust Vandecandelaere, et al.
Pharmacology & Therapeutics (2024) Vol. 259, pp. 108667-108667
Closed Access | Times Cited: 4
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Kenji Nakano
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3540-3540
Open Access | Times Cited: 18
Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
Dongming Yan, Weicheng Li, Qibing Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Targeting Nutrient Dependency in Cancer Treatment
Kexin Fan, Zhan Liu, Min Gao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells
Xiaohui Yang, Shifeng Tian, Linlin Fan, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 17
The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer
Eleazer P. Resurreccion, Ka-wing Fong
Metabolites (2022) Vol. 12, Iss. 6, pp. 488-488
Open Access | Times Cited: 17
Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma
Feng Tang, Zhiyong Pan, Yi Wang, et al.
Neuroscience Bulletin (2022) Vol. 38, Iss. 9, pp. 1069-1084
Open Access | Times Cited: 17
The metabolomic landscape plays a critical role in glioma oncogenesis
Kenta Masui, Webster K. Cavenee, Paul S. Mischel, et al.
Cancer Science (2022) Vol. 113, Iss. 5, pp. 1555-1563
Open Access | Times Cited: 16
Normal and Neoplastic Growth Suppression by the Extended Myc Network
Edward V. Prochownik, Huabo Wang
Cells (2022) Vol. 11, Iss. 4, pp. 747-747
Open Access | Times Cited: 16

Scroll to top